A medical nutriment has supportive value in the treatment of colorectal cancer
Á. Balogh, A. Hoffmann, Á. Mayer, A. Telekes, A. Vágvölgyi, F. Jakab, F. Szetntpétery, K. Lapis, L. Thurzó, M. Hidvégi, M. Nichelatti, P. Sápy, Y. Shoenfeld, Zs. Kahán
British Journal of Cancer, 2003
Abstract
Avemar (MSC) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus Avemar (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients’ choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (»)